ReviewInternational journal of molecular sciences2025
Single-Cell Multi-Omics in Type 2 Diabetes Mellitus: Revealing Cellular Heterogeneity and Mechanistic Insights.
Yijie Wei, Feitong Hong, Sijia Xie, Xinwei Luo, Xiaolong Li, Fuying Dao, Kejun Deng, Hao Lin, Hao Lyu
Abstract readReview
In one paragraphReview in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Yijie WeiDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China.ORCID 0009-0002-3000-3205 Feitong HongDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China.ORCID 0009-0004-0064-0961 Sijia XieDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China.
Xinwei LuoDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China.
Xiaolong LiDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China.
Fuying DaoSchool of Biological Sciences, Nanyang Technological University, Singapore 639798, Singapore.ORCID 0000-0001-5285-6044 Kejun DengDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China.ORCID 0000-0003-0411-549X Hao LinDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China.ORCID 0000-0001-6265-2862 Hao LyuDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China.ORCID 0000-0002-7580-0155 Funding
China Postdoctoral Science Foundation 2023TQ0047, GZC20230380National Natural Science Foundation of China 82130112, 62402089, U24A20789Sichuan Science and Technology Program 2025ZNSFSC1465
6 · The paper itselfAbstract
Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder characterized by insulin resistance, progressive β-cell dysfunction, and severe systemic complications. Advances in single-cell multi-omics-transcriptomics, chromatin accessibility profiling, and integrative analyses-have offered unprecedented insights into the cellular heterogeneity and regulatory networks of pancreatic islets. We highlight recent discoveries in islet cell heterogeneity and β-cell pathophysiology, with a particular focus on dysfunction and dedifferentiation. We further underscore the computational frameworks that enable these discoveries, spanning data preprocessing, multi-omics integration, and machine learning-driven analyses, which collectively enable the dissection of disease-relevant cell subpopulations and the reconstruction of developmental and regulatory trajectories. We also examine how impaired signaling within islets and chronic adipose inflammation contribute to T2DM pathogenesis. Finally, we discuss key challenges in clinical translation-including limited population diversity in single-cell atlases and the interpretability of computational models-and propose future directions toward precision diagnostics and therapeutic innovation in T2DM.
Indexed as
Diabetes Mellitus, Type 2Single-Cell AnalysisAnimalsGenomicsHumansInsulin-Secreting CellsIslets of LangerhansMultiomicscellular heterogeneityepigenomicssingle-cell multi-omicstype 2 diabetes mellitusβ-cell dysfunction
Identifiers
PMID41303487
PMCPMC12652634
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390